ArticleCase reports in oncology
Uncommon Complication of Transarterial Chemoembolization with Doxorubicin: A Case of Post-TACE Neutropenia in Hepatocellular Carcinoma.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transarterial chemoembolization (TACE) using doxorubicin is an established treatment option for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients. In this case report, we describe a rare occurrence of delayed febrile neutropenia following conventional TACE (C-TACE) with doxorubicin. This complication, while recognized with systemic doxorubicin, is rarely documented in the context of C-TACE. Case Presentation: We present a 53-year-old Bangladeshi man with hepatitis B-related HCC who developed febrile neutropenia 2 weeks following C-TACE with doxorubicin. Indeed, previous C-TACE procedures had also resulted in similar neutropenic episodes, which pointed to the association of C-TACE with doxorubicin and neutropenia. Conclusion: The case brings attention and vigilance to the monitoring for neutropenia in patients receiving C-TACE with doxorubicin, an association rarely currently documented in the literature. Further studies are needed to assess its prevalence and identify risk factors and management strategies for this complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.